专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

ES2395555T3 Formulación liposomal para la administración oral de glutatión (reducido) 未知
公开(公告)号：ES2395555T3
公开(公告)日：2013-02-13
申请号：ES05851408
申请日：2005-11-07
申请人： GUILFORD F TIMOTHY , YOUR ENERGY SYSTEMS LLC
发明人： GUILFORD F TIMOTHY
IPC分类号： A61K9/127 , A61K9/48 , A61K31/198 , A61K38/06
摘要： Bebida o pulverizador de glutatión liposomal que consiste en:71,9 % p/p de agua desionizada,15,00 % p/p de glicerina,2,50 % p/p de polisorbato-20,1,50 % p/p de lecitina,0,50 % p/p de extracto de semilla de cítrico,0,10 % p/p de sorbato de potasio, y8,50 % p/p de glutatión reducido.

2. 发明公开

EP1868572A4 ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA INTRAVENOUS OR ENCAPSULATED IN LIPOSOME FOR TREATMENT OF TNF-ALPHA EFFECTS AND ELU-LIKE VIRAL SYMPTOMS 审中-公开
标题翻译：（还原的）谷胱甘肽行政通过静脉内途径或在脂质体中包封的对TNF-ALPHA-效应及流感样症状病毒性肝炎的治疗
公开(公告)号：EP1868572A4
公开(公告)日：2011-03-09
申请号：EP06739896
申请日：2006-03-29
申请人： GUILFORD F TIMOTHY
发明人： GUILFORD F TIMOTHY
IPC分类号： A61K9/127 , A61K33/04 , A61K38/06 , A61K47/10 , A61P31/16
CPC分类号： A61K38/063 , A61K9/0019 , A61K9/006 , A61K9/0095 , A61K9/06 , A61K9/127 , A61K9/4825 , A61K31/13 , A61K31/196 , A61K33/04 , A61K45/06 , C12N2760/16011 , A61K2300/00

3. 发明公开

EP2519227A4 MANAGEMENT OF MYOCLONUS WITH ORAL LIPOSOMAL REDUCED GLUTATHIONE 审中-公开
标题翻译： MYOKLONUSMANAGEMENT口服脂质体还原型谷胱甘肽
公开(公告)号：EP2519227A4
公开(公告)日：2014-08-06
申请号：EP10841709
申请日：2010-12-30
申请人： GUILFORD F TIMOTHY
发明人： GUILFORD F TIMOTHY
IPC分类号： A61K9/127 , A61K31/40 , A61P25/00 , A61P25/08
CPC分类号： A61K31/40 , A61K9/0014 , A61K9/0019 , A61K9/0053 , A61K9/006 , A61K9/0095 , A61K9/12 , A61K9/127 , A61K9/1271 , A61K9/4858 , A61K38/063 , A61K45/06 , A61K2300/00

4. 发明专利

CA2628777C LIPOSOMAL FORMULATION FOR ORAL ADMINISTRATION OF GLUTATHIONE (REDUCED) 未知
公开(公告)号：CA2628777C
公开(公告)日：2016-09-13
申请号：CA2628777
申请日：2005-11-07
申请人： GUILFORD F TIMOTHY , KELLER BRIAN CHARLES
发明人： GUILFORD F TIMOTHY , KELLER BRIAN CHARLES
IPC分类号： A61K9/127
摘要： The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

6. 发明专利

PL1817006T3 LIPOSOMALNY PREPARAT DO DOUSTNEGO PODAWANIA GLUTATIONU (ZREDUKOWANEGO) 未知
公开(公告)号：PL1817006T3
公开(公告)日：2013-03-29
申请号：PL05851408
申请日：2005-11-07
申请人： GUILFORD F TIMOTHY
发明人： GUILFORD F TIMOTHY
IPC分类号： A61K9/127 , A61K9/48 , A61K31/198 , A61K38/06

7. 发明申请

WO2007115131A3 LIPOSOMAL REDUCED GLUTATHIONE AND 1-ARGININE, INCLUDING OTHER INGREDIENT(S) 审中-公开
标题翻译：脂质减少的GLUTATHIONE和1-ARGININE，包括其他成分（S）
公开(公告)号：WO2007115131A3
公开(公告)日：2008-11-20
申请号：PCT/US2007065552
申请日：2007-03-29
申请人： GUILFORD F TIMOTHY
发明人： GUILFORD F TIMOTHY
IPC分类号： A61K38/06
CPC分类号： A61K9/0095 , A61K9/127
摘要： The invention enables management of mammalian disease related to decreased energy production in the mitochondria, the powerhouse of the cell. The invention uses the combination of liposomal reduced glutathione and 1-arginine to increase the ability weight loss in individuals with excess weight. The mechanism of weight loss appears to be related to improving the inefficient production of energy by the respiratory transport chain of mitochondria, the function of which are influenced positively by the availability of antioxidant nitric oxide in a non-oxidized environment. This invention enables weight loss in individuals who's inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production. The pathways related to inability to lose weight are also related to the phenomenon of the inability to metabolize fats, which results in insulin resistance and diabetes. The invention is useful for the management of the metabolic syndrome. The metabolic syndrome is actually a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well generally in the body is part of the benefit of the combination of liposomal reduced glutathione and 1-arginine. In addition, the biochemical pathways stimulated by this invention can have a beneficial effect in individuals suffering from a variety of infectious diseases.
摘要翻译：本发明能够管理哺乳动物疾病与线粒体（细胞的发电厂）中的能量产生减少有关。本发明使用脂质体还原型谷胱甘肽和1-精氨酸的组合来增加体重过重的个体的能力减轻。体重减轻的机制似乎与线粒体呼吸运输链改善能量效率低下有关，其功能受到非氧化环境中抗氧化一氧化氮的可用性的积极影响。本发明使得不能减肥的个体的体重减轻与促进线粒体功能和能量产生的生物化学途径的低效率有关。与无法减肥有关的途径也与脂肪代谢不能现象有关，导致胰岛素抵抗和糖尿病。本发明可用于代谢综合征的治疗。代谢综合征实际上是与血管疾病问题风险增加相关的一组代谢因素。本发明也可用于解决伴随体重增加和疾病的疲劳。本发明增加中枢神经系统生物化学丁胺的生成能力以及通常在体内的能力是脂质体还原型谷胱甘肽与1-精氨酸组合的益处之一。此外，本发明刺激的生物化学途径可以对患有各种感染性疾病的个体产生有益的作用。

8. 发明申请

WO2006060120A3 LIPOSOMAL FORMULATION FOR ORAL ADMINISTRATION OF GLUTATHIONE (REDUCED) 审中-公开
标题翻译：口服给予谷胱甘肽的脂质体制剂（减少）
公开(公告)号：WO2006060120A3
公开(公告)日：2006-09-14
申请号：PCT/US2005040308
申请日：2005-11-07
申请人： GUILFORD F TIMOTHY
发明人： GUILFORD F TIMOTHY
IPC分类号： A61K9/127
CPC分类号： A61K9/127 , A61K31/198 , A61K33/04 , A61K38/05 , A61K38/063 , A61K2300/00
摘要： The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.
摘要翻译：本发明是口服提供全身性谷胱甘肽（还原）的组合物和通过在脂质体包封中口服谷胱甘肽（还原）而提供全身谷胱甘肽的方法。施用治疗有效量的口服脂质体谷胱甘肽（减少的）导致与谷胱甘肽缺乏相关的疾病状态如帕金森病和囊性纤维化的症状改善。考虑了增强脂质体谷胱甘肽作用的化合物，例如硒，EDTA，卡比多巴和左旋多巴。

9. 发明申请

WO2007053810A3 LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, INCLUDING WITH OTHER PHARMACOLOGIC PREPARATION, CAPABLE OF ADMINISTRATION AS AN ORAL, TOPICAL, INTRAORAL OR TRANSMUCOSAL, PREPARATION, FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DE 审中-公开
标题翻译：包括其他药理学制剂，可作为口服，局部，局部或透膜给药，制备，用于逆转和防止胆固醇和低含量的氧化作用的脂质体包封的还原谷胱甘肽
公开(公告)号：WO2007053810A3
公开(公告)日：2007-11-22
申请号：PCT/US2006060271
申请日：2006-10-26
申请人： GUILFORD F TIMOTHY , SCHUMM BROOKE III
发明人： GUILFORD F TIMOTHY , SCHUMM BROOKE III
IPC分类号： A61K9/127 , A61K38/00
CPC分类号： A61K9/127 , A61K9/4808 , A61K31/122 , A61K31/198 , A61K31/366 , A61K33/04 , A61K38/00 , A61K38/05 , A61K38/063 , A61K45/06 , A61K2300/00
摘要： The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQl0 as a therapy for vascular disease and management of side effects of statin therapy.
摘要翻译：本发明提出了确定脂质体中的还原型谷胱甘肽（脂质体还原型谷胱甘肽）用于口服给药治疗有效量以改善血管疾病的进展，所述血管疾病包括动脉粥样硬化，糖尿病，高血压，导致血流减少的动脉变窄，局部缺血通过减少氧化的胆固醇，氧化的HDL和氧化的LDL的量和作用，发生血栓形成，血块形成，异常血小板聚集和血栓形成事件。本发明还提出将脂质体包封的谷胱甘肽与他汀类药物组合以改善不仅降低胆固醇而且降低氧化胆固醇以及氧化HDL和氧化LDL的效果。本发明还提出将脂质体包封的谷胱甘肽与辅酶Q10组合用作血管疾病的治疗和他汀类药物治疗的副作用的管理。

10. 发明申请

WO2007053810A9 LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, INCLUDING WITH OTHER PHARMACOLOGIC PREPARATION, CAPABLE OF ADMINISTRATION AS AN ORAL, TOPICAL, INTRAORAL OR TRANSMUCOSAL, PREPARATION, FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DE 审中-公开
标题翻译：包括减脂的GLUTATHIONE，包括其他药理学准备，能够作为口服，局部，内服或转运的管理，制备，反向和预防氧化胆固醇和低密度脂蛋白
公开(公告)号：WO2007053810A9
公开(公告)日：2007-10-11
申请号：PCT/US2006060271
申请日：2006-10-26
申请人： GUILFORD F TIMOTHY , SCHUMM BROOKE III
发明人： GUILFORD F TIMOTHY , SCHUMM BROOKE III
IPC分类号： A61K9/127 , A61K38/00
CPC分类号： A61K9/127 , A61K9/4808 , A61K31/122 , A61K31/198 , A61K31/366 , A61K33/04 , A61K38/00 , A61K38/05 , A61K38/063 , A61K45/06 , A61K2300/00
摘要： The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQl0 as a therapy for vascular disease and management of side effects of statin therapy.
摘要翻译：本发明提出在脂质体（脂质体还原型谷胱甘肽）中确保还原型谷胱甘肽以口服给药治疗有效量以改善血管疾病进展，包括动脉粥样硬化，糖尿病，高血压，导致血流减少的动脉狭窄，缺血性事件，血栓形成，血小板聚集异常和血栓形成事件，减少氧化胆固醇，氧化型HDL和氧化LDL的量和作用。本发明还提出将脂质体包封的谷胱甘肽与他汀类药物组合以改善不仅降低胆固醇而且降低氧化的胆固醇以及氧化的HDL和氧化的LDL的作用。本发明还提出将脂质体包封的谷胱甘肽与CoQ10组合作为血管疾病的治疗和他汀类药物治疗的副作用的管理。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式